Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2009

Open Access 01-12-2009 | Original investigation

Blood pressure control and components of the metabolic syndrome: the GOOD survey

Authors: Walter Zidek, Lisa Naditch-Brûlé, Stefano Perlini, Csaba Farsang, Sverre E Kjeldsen

Published in: Cardiovascular Diabetology | Issue 1/2009

Login to get access

Abstract

Background

The GOOD (Global Cardiometabolic Risk Profile in Patients with Hypertension Disease) survey showed that blood pressure control was significantly worse in hypertensive patients with metabolic syndrome and/or diabetes mellitus than in those with essential hypertension only. This analysis aimed to investigate which components of the metabolic syndrome are primarily associated with poor blood pressure control.

Methods

The GOOD survey was designed as an observational cross-sectional survey in 12 European countries to assess the cardiometabolic risk profile in patients with essential hypertension. Investigators were randomly selected from a list of general practitioners (70% of investigators) and a list of specialists such as internists, cardiologists and hypertension specialists (30% of investigators). Data from 3,280 outpatients with hypertension, aged at least 30 years who were receiving antihypertensive treatment or had newly diagnosed hypertension according to the European Society of Hypertension and the European Society of Cardiology criteria, were included in the analyses. Blood pressure control, body mass index (BMI), waist circumference, serum triglycerides, total and high density lipoprotein (HDL) cholesterol measurements were compared in patients with diabetes mellitus and metabolic syndrome, with diabetes mellitus only, with metabolic syndrome only, and with neither metabolic syndrome nor diabetes mellitus.

Results

The highest blood pressure values were found in patients with metabolic syndrome with or without diabetes mellitus. Blood pressure was significantly lower in patients with diabetes mellitus only. The highest BMI, waist circumference and serum triglycerides, and the lowest HDL cholesterol levels among the groups studied occurred in patients with metabolic syndrome, either with or without diabetes mellitus.

Conclusion

Among the components of the metabolic syndrome, it is not impaired glucose tolerance which is associated with the poor response to antihypertensive treatment. Instead, visceral obesity and dyslipidemia components of the metabolic syndrome, i.e. hypertriglyceridemia and low HDL cholesterol levels, are associated with resistance to antihypertensive treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C: Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens. 2008, 26: 2064-2070. 10.1097/HJH.0b013e32830c45c3.CrossRefPubMed Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C: Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens. 2008, 26: 2064-2070. 10.1097/HJH.0b013e32830c45c3.CrossRefPubMed
2.
go back to reference Farsang C, Naditch-Brule L, Perlini S, Zidek W, Kjeldsen SE: Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. J Hum Hypertens. 2009, 23: 316-324. 10.1038/jhh.2008.136.CrossRefPubMed Farsang C, Naditch-Brule L, Perlini S, Zidek W, Kjeldsen SE: Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. J Hum Hypertens. 2009, 23: 316-324. 10.1038/jhh.2008.136.CrossRefPubMed
3.
go back to reference Ritchie SA, Ewart MA, Perry CG, Connell JM, Salt IP: The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond). 2004, 107: 519-532.CrossRef Ritchie SA, Ewart MA, Perry CG, Connell JM, Salt IP: The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond). 2004, 107: 519-532.CrossRef
4.
go back to reference Aldhahi W, Hamdy O: Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep. 2003, 3: 293-298. 10.1007/s11892-003-0020-2.CrossRefPubMed Aldhahi W, Hamdy O: Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep. 2003, 3: 293-298. 10.1007/s11892-003-0020-2.CrossRefPubMed
5.
go back to reference Guerre-Millo M: Adipose tissue and adipokines: for better or worse. Diabetes Metab. 2004, 30: 13-19. 10.1016/S1262-3636(07)70084-8.CrossRefPubMed Guerre-Millo M: Adipose tissue and adipokines: for better or worse. Diabetes Metab. 2004, 30: 13-19. 10.1016/S1262-3636(07)70084-8.CrossRefPubMed
6.
go back to reference Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S: Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005, 288: H2031-2041. 10.1152/ajpheart.01058.2004.CrossRefPubMed Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S: Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005, 288: H2031-2041. 10.1152/ajpheart.01058.2004.CrossRefPubMed
7.
go back to reference Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED: Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension. 2007, 49: 1455-1461. 10.1161/HYPERTENSIONAHA.107.086835.CrossRefPubMed Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED: Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension. 2007, 49: 1455-1461. 10.1161/HYPERTENSIONAHA.107.086835.CrossRefPubMed
8.
go back to reference Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003, 42: 231-234. 10.1161/01.HYP.0000083488.67550.B8.CrossRefPubMed Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003, 42: 231-234. 10.1161/01.HYP.0000083488.67550.B8.CrossRefPubMed
9.
go back to reference Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia R: Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 2007, 117: 1718-1726. 10.1172/JCI29623.PubMedCentralCrossRefPubMed Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia R: Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 2007, 117: 1718-1726. 10.1172/JCI29623.PubMedCentralCrossRefPubMed
10.
go back to reference Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, Lam KS: Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004, 89: 765-769. 10.1210/jc.2003-031012.CrossRefPubMed Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, Lam KS: Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004, 89: 765-769. 10.1210/jc.2003-031012.CrossRefPubMed
11.
go back to reference Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K: Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes. 2007, 56: 804-808. 10.2337/db06-1405.CrossRefPubMed Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K: Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes. 2007, 56: 804-808. 10.2337/db06-1405.CrossRefPubMed
12.
go back to reference Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003, 278: 45021-45026. 10.1074/jbc.M307878200.CrossRefPubMed Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003, 278: 45021-45026. 10.1074/jbc.M307878200.CrossRefPubMed
13.
go back to reference Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, Muellner C, Speiser W, Wagner O: Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 2002, 90: 711-718. 10.1161/01.RES.0000014226.74709.90.CrossRefPubMed Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, Muellner C, Speiser W, Wagner O: Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 2002, 90: 711-718. 10.1161/01.RES.0000014226.74709.90.CrossRefPubMed
14.
go back to reference Bouloumie A, Marumo T, Lafontan M, Busse R: Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999, 13: 1231-1238.PubMed Bouloumie A, Marumo T, Lafontan M, Busse R: Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999, 13: 1231-1238.PubMed
15.
go back to reference Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003, 289: 1799-1804. 10.1001/jama.289.14.1799.CrossRefPubMed Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003, 289: 1799-1804. 10.1001/jama.289.14.1799.CrossRefPubMed
16.
go back to reference Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000, 11: 327-332. 10.1016/S1043-2760(00)00301-5.CrossRefPubMed Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab. 2000, 11: 327-332. 10.1016/S1043-2760(00)00301-5.CrossRefPubMed
17.
go back to reference Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP: Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens. 1994, 12: 1433-1437. 10.1097/00004872-199412000-00018.CrossRefPubMed Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP: Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens. 1994, 12: 1433-1437. 10.1097/00004872-199412000-00018.CrossRefPubMed
18.
go back to reference Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001, 14: 103S-115S. 10.1016/S0895-7061(01)02077-5.CrossRefPubMed Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001, 14: 103S-115S. 10.1016/S0895-7061(01)02077-5.CrossRefPubMed
19.
go back to reference Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002, 324: 127-137. 10.1097/00000441-200209000-00003.CrossRefPubMed Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002, 324: 127-137. 10.1097/00000441-200209000-00003.CrossRefPubMed
20.
go back to reference Garrison RJ, Kannel WB, Stokes J, Castelli WP: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987, 16: 235-251. 10.1016/0091-7435(87)90087-9.CrossRefPubMed Garrison RJ, Kannel WB, Stokes J, Castelli WP: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987, 16: 235-251. 10.1016/0091-7435(87)90087-9.CrossRefPubMed
21.
go back to reference Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ: Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008, 52: 818-827. 10.1161/HYPERTENSIONAHA.108.113357.CrossRefPubMed Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ: Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008, 52: 818-827. 10.1161/HYPERTENSIONAHA.108.113357.CrossRefPubMed
22.
go back to reference Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY: Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004, 140: 992-1000.CrossRefPubMed Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY: Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med. 2004, 140: 992-1000.CrossRefPubMed
23.
go back to reference Wildman RP, Sutton-Tyrrell K, Newman AB, Bostom A, Brockwell S, Kuller LH: Lipoprotein levels are associated with incident hypertension in older adults. J Am Geriatr Soc. 2004, 52: 916-921. 10.1111/j.1532-5415.2004.52258.x.CrossRefPubMed Wildman RP, Sutton-Tyrrell K, Newman AB, Bostom A, Brockwell S, Kuller LH: Lipoprotein levels are associated with incident hypertension in older adults. J Am Geriatr Soc. 2004, 52: 916-921. 10.1111/j.1532-5415.2004.52258.x.CrossRefPubMed
24.
go back to reference Nofer JR, Giet van der M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004, 113: 569-581.PubMedCentralCrossRefPubMed Nofer JR, Giet van der M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004, 113: 569-581.PubMedCentralCrossRefPubMed
25.
go back to reference Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G: The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008, 26: 1891-1900. 10.1097/HJH.0b013e328302ca38.CrossRefPubMed Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G: The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008, 26: 1891-1900. 10.1097/HJH.0b013e328302ca38.CrossRefPubMed
26.
go back to reference Hanefeld M, Koehler C, Gallo S, Benke I, Ott P: Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol. 2007, 6: 13-10.1186/1475-2840-6-13.PubMedCentralCrossRefPubMed Hanefeld M, Koehler C, Gallo S, Benke I, Ott P: Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol. 2007, 6: 13-10.1186/1475-2840-6-13.PubMedCentralCrossRefPubMed
Metadata
Title
Blood pressure control and components of the metabolic syndrome: the GOOD survey
Authors
Walter Zidek
Lisa Naditch-Brûlé
Stefano Perlini
Csaba Farsang
Sverre E Kjeldsen
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2009
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-8-51

Other articles of this Issue 1/2009

Cardiovascular Diabetology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.